Central venous catheters are a lifeline in intensive care — and a leading source of preventable hospital-acquired infections. Bloodstream infections tied to these devices carry mortality rates exceeding 20%, making any intervention that could reduce their incidence a high-stakes clinical question. This randomized trial directly tests whether a 4% tetrasodium EDTA (t-EDTA) locking solution — a chelating agent with antimicrobial and antibiofilm properties — can outperform standard locking fluid in reducing a composite of catheter-associated bloodstream infections, occlusions requiring alteplase, and catheter removal due to blockage in adult ICU patients.
The trial assessed this composite endpoint across adult ICU patients receiving central venous access devices, comparing t-EDTA lock solution against a control. The t-EDTA compound works by binding divalent cations such as calcium and magnesium that bacteria rely on for biofilm formation, theoretically disrupting the microbial colonization that precedes bloodstream infection. The randomized design provides the strongest available evidence for or against this mechanism translating into measurable clinical benefit under real-world ICU conditions.
t-EDTA has been an area of genuine research interest for over a decade, with earlier smaller studies and in vitro data suggesting meaningful antibiofilm activity. This trial represents a higher-evidentiary-tier test of that promise. The critical limitation is that ICU populations are heterogeneous — immunosuppression, catheter dwell time, insertion site, and nursing practices all independently influence infection rates, potentially diluting or confounding treatment effects. The composite endpoint, while pragmatic, also bundles outcomes of differing clinical severity and pathophysiology, which can obscure signal in individual components. For health-conscious adults and clinicians alike, the takeaway is that mechanistically plausible interventions do not always survive rigorous trial conditions. This finding should inform hospital formulary decisions and redirect research toward combination lock solutions or enhanced insertion-site antisepsis protocols.